Medical Practice Valuation Multiples by Specialty: 2026 Report
Medical practice valuation multiples for 12 specialties from 24 published sources, with full methodology: why size moves the number more than specialty.
In this article
- Key findings
- Medical practice valuation multiples by specialty: all published ranges
- Why size moves medical practice valuation multiples more than specialty
- Size tiers across sources
- Where the sources disagree, and why
- Smaller practices: SDE and revenue multiples
- Market context for 2026
- How buyer type changes the multiple
- What moves your practice within its range
- Methodology
- Sources by type
- Get a real number for your practice
- Frequently asked questions about medical practice valuation multiples
We compiled every published set of medical practice valuation multiples we could verify — 103 data points from 24 pages across 11 publishers, covering 12 specialties, checked in October 2026. The headline ranges are enormous: cardiology is quoted anywhere from 4× to 18× EBITDA, ophthalmology from 5× to 20×. But almost all of that spread is size, not specialty. A solo or owner-dependent practice is quoted at 3–8× in every specialty studied, and 3–7× in seven of nine. The 12–20× figures apply only at platform scale. Full data and methodology are below.
Physicians and dentists researching what their practice is worth run into the same problem. Every bank, advisory firm and broker publishes a different range. None of them cite each other. And the numbers quoted most loudly are the largest ones. This report does the aggregation of medical practice valuation multiples that nobody else has done.
We collected every range published by a named source that we could verify directly. We recorded each figure exactly as stated and tabulated the results by specialty and by practice size. Three things stand out. They are detailed in the sections that follow. For how these numbers are actually applied to a practice, see our complete guide to medical practice valuation.
Key findings
- Size explains more of the range than specialty does. Nine specialties have a published small-practice figure. Every one lands between 3× and 8× adjusted EBITDA, and seven of the nine between 3× and 7×. The specialty premiums that make headlines appear only at the mid and platform tiers.
- Sources agree at the bottom and disagree at the top. Small-practice bands span at most 5 turns in any specialty. Platform bands span up to 13 turns (ophthalmology, 7–20×). So the numbers least relevant to an independent owner have the least consensus.
- The top of the market has compressed. The most cited macro figure in these sources is that the median EV/EBITDA multiple for publicly traded healthcare-services companies fell to roughly 11.5× in 2025 from 14.5× the prior year. That matters for platform pricing far more than for a single-location practice.
- Almost none of this is transaction data. Of the 24 sources, most publish advisory or brokerage ranges. Only three describe a transaction basis. Treat every figure here, including ours, as orientation rather than pricing.
Medical practice valuation multiples by specialty: all published ranges
Each row aggregates every figure we verified for that specialty. Published range is the lowest low and highest high any source stated, across all practice sizes. The three tier columns show the same data bucketed by size. Small means solo, owner-dependent, under roughly $1M EBITDA, or an individual/SBA buyer. Mid means multi-provider, roughly $1–3M EBITDA, or an add-on to an existing platform. Platform means roughly $3M+ EBITDA or a platform-grade buyer. A dash means no source published a figure for that tier.
| Specialty | Sources | Published range | Small / independent | Mid / add-on | Platform |
|---|---|---|---|---|---|
| Dental | 5 | 3–12× | 3–7× | 5–9× | 6–12× |
| Dermatology | 7 | 3–15× | 3–7× | 4–8.3× | 7–15× |
| Ophthalmology | 4 | 5–20× | 5–6.5× | 6–11× | 7–20× |
| Gastroenterology | 4 | 5–16× | 5–7× | 7–9× | 10–16× |
| Orthopedics | 5 | 4–15× | 4–6× | 6–11× | 9–15× |
| Cardiology | 4 | 4–18× | 4–8× | 8–12× | 10–18× |
| Primary care | 4 | 3–12× | — | 3–6.2× | 4–12× |
| Behavioral health | 4 | 3–14× | 3–8× | 4–10× | 6–14× |
| Medical spa / aesthetics | 4 | 3–12× | 3–7× | 4–8× | 5–12× |
| Veterinary | 3 | 3.5–15× | 3.5–7× | 6–12× | 8–15× |
| Physical therapy | 3 | 2–12.3× | — | 7.8× | 6–12.3× |
| Plastic surgery | 5 | 4–12× | — | 4–11.3× | 8–12× |
Adjusted EBITDA multiples unless stated. “Sources” counts distinct published pages verified for that specialty; several publishers contribute more than one page. Physical therapy’s mid figure (7.8×) is an average add-on multiple rather than a range, and its overall low (2×) is a single source quoting a typical range for small practices. Primary care, physical therapy and plastic surgery had no source that published a distinct small-practice EBITDA figure. Verified 29 October 2026; see methodology below.
Wondering how this applies to your practice? A Tenet advisor can walk you through it in a confidential call.
Talk to an advisorWhy size moves medical practice valuation multiples more than specialty
Read down the small / independent column and the specialty labels almost stop mattering. Sources quote a solo dental practice, a solo dermatology practice, a single-DVM veterinary clinic and an owner-operated med spa at roughly the same 3–7×. Cardiology and behavioral health reach 8× at the top of their small-practice bands. That is the full extent of the specialty effect at this tier.
The reason is structural. At small scale the buyer is usually an individual clinician financing the purchase through a bank or SBA loan. The lender underwrites cash flow against the price, and that caps the multiple regardless of specialty. The buyer also takes on concentration risk — when the owner leaves, so may the production — and prices that risk the same way in every field.
Specialty begins to matter at the mid tier. That is where add-on buyers for existing platforms appear and pay for the things that differ by specialty: ancillaries, procedure mix, payer mix, and how easily the practice slots into a roll-up. It dominates at the platform tier. There, ophthalmology with owned ASCs, cardiology with imaging and cath labs, or a multi-state dermatology group can command figures with no equivalent in primary care.
The practical implication for an owner is uncomfortable but useful: the quickest way to change your multiple is rarely to change your specialty’s reputation; it is to change your tier. That means adding associate providers, building ancillary revenue, and reducing dependence on yourself. Those are the levers that move a practice from the left column toward the right. Most of them take one to three years. See how practice size influences deals and what drives higher or lower valuations.
Size tiers across sources
Four sources publish cross-specialty medical practice valuation multiples by adjusted EBITDA tier. They do not use identical cut-offs, but the shape is the same in each: roughly a turn or two added at each step up in scale.
| EBITDA | Source 1 | Source 2 | Source 3 | Source 4 |
|---|---|---|---|---|
| Under $1M | 5–7× | to ~6× | 3–6× | — |
| $1–3M | 7–9× | 5–9× | 5–10× | 5.6× |
| $3–5M | 9–11× | 7–11× | 8–12× | 7.1× |
| Over $5M | 11–13× | 9–13×+ | 10–15× | 8.8× |
Adjusted EBITDA. Sources 1, 2 and 4 are three separate publications from one investment bank; source 3 is an M&A law firm’s guide. Tier boundaries differ slightly by source: source 2 starts from asset value at the bottom tier and uses $3–7M and $7M+ for the upper two; source 3 uses under $500K, $500K–$2M, $2–5M and over $5M; source 4 gives point values for multi-specialty practices at $1–3M, $3–5M and $5–10M.
Where the sources disagree, and why
The disagreement is concentrated at the top. One source quotes ophthalmology platforms at 7–11× and another at 12–20×. Two sources put gastroenterology platforms at 10–14× and a third at 13–16×. Cardiology appears at 10–14×, 12–15× and 10–18×. Several things explain the gaps in published medical practice valuation multiples, and none of them is that one source is simply wrong.
- Different earnings definitions. Some sources apply multiples to post-MSO EBITDA — earnings after paying physician-owners a market clinical wage — which is a smaller number than owner-benefit EBITDA, so the same deal shows a higher multiple. One source states this explicitly; most do not say which they use.
- Different buyer universes. A range describing single-bidder add-on offers will sit below one describing a competitive process. One veterinary source conditions its figures on a competitive process; most sources do not say.
- Outliers pulling the top. A retina platform transaction reported at 18.4×, an oncology deal structured around a 19× put/call, and veterinary platform prints in the high teens all widen the platform bands without saying much about a typical practice.
- Vintage. Pages carry update dates from mid-2025 to October 2026, across a period in which the public healthcare-services median fell from 14.5× to about 11.5×. Older pages lean higher.
Where sources agree is more informative: the small-practice tier, where a lender-constrained individual buyer sets the ceiling in every specialty.
Smaller practices: SDE and revenue multiples
Below roughly $1M of earnings, most practices are not valued on EBITDA at all. They are valued on Seller’s Discretionary Earnings — earnings with the owner’s own compensation added back — or sanity-checked against revenue. We found only one marketplace-based figure. It draws on a national business-for-sale marketplace’s 2021–2025 closings and puts medical practices at 1.46× to 2.94× SDE, with a median of 2.05×. Advisory sources give 1–3× SDE for smaller practices, and 0.5–1.0× revenue for small-to-mid practices as a cross-check. In dentistry the percentage-of-collections convention persists. Sources commonly cite 60–85% of annual collections for general practices sold doctor-to-doctor.
Because SDE and EBITDA are different bases, their multiples are not comparable, and a 2× SDE figure and a 5× EBITDA figure can describe the same practice. See the role of EBITDA in valuation.
Market context for 2026
The most cited macro figure across these sources is the compression in public-market multiples. The median EV/EBITDA multiple for publicly traded healthcare-services companies fell to approximately 11.5× in 2025 from 14.5× in 2024. That compression bears most directly on platform pricing, meaning the exit multiple a private-equity sponsor can expect. It then flows down to what platforms will pay for add-ons. It has little direct effect on a solo practice sold to an individual buyer, because a lender sets that price. For more on the mechanism, read the effect of interest rates on valuations.
How buyer type changes the multiple
Who buys the practice can matter as much as what is sold. The same practice attracts very different multiples depending on the buyer’s strategy:
- Private-equity platforms and MSOs/DSOs pay the highest multiples for practices that fit a roll-up, because they can add scale and resell at a larger platform multiple — see selling to private equity. Published ranges put PE-backed MSO platforms at 8–14× post-MSO EBITDA for practices above $2M.
- Hospitals and health systems value strategic fit, referrals and coverage; two sources independently place health-system buyers at 5–8×.
- Individual physician buyers pay the lowest multiples and rely on financing, but are often the best fit for a smaller practice or an internal succession.
Running a competitive process across several buyer types is usually the most effective way to move from the bottom of a range to the top. That is the core of what a sell-side advisor does.
What moves your practice within its range
Specialty and size set the range. Fundamentals decide where a practice lands in it. Sources cite five factors most often for the top of a band. Consistent revenue and volume growth. Associate providers who reduce dependence on the selling clinician. A diversified payer and referral base. Ancillary and cash-pay revenue. Clean financials with secure leases and staffing. The factors that pull toward the bottom are the mirror image. One investment bank quantifies several: ancillaries and scale each worth roughly +2–4 turns, growth +1–3, geographic density +1–2, and payer mix ±1.5–2. See what buyers value most.
Methodology
This report aggregates published medical practice valuation multiples. It is not transaction data, and it is not Tenet M&A’s own deal data.
- What was included. Pages from investment banks, M&A advisory firms, brokers, software vendors, a national business-for-sale marketplace, a law firm and industry commentators. Each states a numeric multiple range for a healthcare practice segment and is dated 2025 or 2026. We reviewed one healthcare-consultancy piece from 2023 on primary care but excluded it from the numeric tables as out of period.
- How figures were verified. We read every figure in the tables directly from the source page on 29 October 2026, either by fetching the page or in a browser. We did not use search-engine summaries or AI-generated digests as sources. Where a page was unreachable, we excluded it rather than quote it second-hand.
- How figures were recorded. Exactly as stated. We record open-ended ranges (“12×+”) at their stated floor and point values as a range of zero width. We note qualitative statements (“high single digits”) but exclude them from numeric aggregation.
- How tiers were assigned. By the source’s own labels where given (solo, add-on, platform, EBITDA band). One advisory table assumes normalized EBITDA above $1M and a scaled buyer; we classified it as platform.
- Why sources are not named here. Most of the 24 pages are published by firms that compete with Tenet M&A for the same clients, and we have chosen not to promote them on this page. Every source is a public web page; the full list with URLs and dates is available on request to info@tenetma.com.
- Limitations. Firms that sell valuation or brokerage services publish most of these sources, and few disclose their data. Ranges reflect each publisher’s view, and several conflict. Nothing here is an appraisal or an offer. An individual practice routinely falls outside every range on this page.
Sources by type
The 24 pages break down as follows. Counts are of pages; a publisher contributing several pages is counted once in the publisher column.
| Source type | Firms | Pages | Data basis stated |
|---|---|---|---|
| Investment banks and valuation firms | 3 | 11 | Three cite a transaction basis; the rest do not |
| M&A advisory and brokerage firms | 4 | 9 | “Proprietary data” or none |
| Software and data vendors | 2 | 2 | Marketplace closings; advisor consensus |
| Industry directory | 1 | 1 | Compiles five dental sources |
| Law firm | 1 | 1 | None stated |
Pages are dated between June 2025 and October 2026. The three transaction-based sources describe observed deals, a 74-deal private-equity platform dataset, and a table compiled from named deal databases.
To cite this report: Tenet M&A, Medical Practice Valuation Multiples by Specialty: 2026 Report, October 2026, tenetma.com/medical-practice-valuation-multiples/. The underlying dataset and source list are available on request.
Get a real number for your practice
A benchmark calibrates expectations; it cannot value a practice. A multiple applied to the wrong earnings figure, or to a practice at the wrong end of its tier, produces a number that feels precise and is simply wrong. Tenet M&A provides confidential, healthcare-specific valuations built on normalised financials and the current buyer landscape for your specialty, and shows the specific steps that could move a practice up its range before going to market. Explore our advisory services or start a confidential conversation. This report is educational and is not an appraisal, an offer, or tax, legal, or investment advice.
Frequently asked questions about medical practice valuation multiples
What multiple do medical practices sell for?
Across 24 published sources, a solo or owner-dependent practice is quoted at roughly 3 to 8 times adjusted EBITDA in every specialty studied, and 3 to 7 times in most. Multi-provider practices and add-ons to existing platforms are quoted at roughly 4 to 12 times depending on specialty, and platform-scale groups at anywhere from 6 to 20 times. Below about $1M of earnings, practices are more often valued on seller’s discretionary earnings, where marketplace data shows a median near 2 times.
Which specialties command the highest valuation multiples?
At platform scale, ophthalmology, cardiology and gastroenterology are quoted highest, with published ranges reaching 16 to 20 times, driven by owned ASCs, imaging and procedural revenue. At small scale the specialty effect largely disappears: every specialty with a published small-practice figure falls between 3 and 8 times, because an individual buyer’s financing sets the ceiling regardless of field.
Why do published multiples vary so much between sources?
Mostly because of size, and then because sources define earnings differently, describe different buyer situations, and were written at different points in a market that compressed from 2024 to 2025. Some apply multiples to post-MSO EBITDA, which is smaller and so shows a higher multiple; some describe competitive processes and others single-bidder offers; and a few headline deals at 18 to 19 times widen the top of the platform ranges. Disagreement is concentrated at the platform tier and is small at the small-practice tier.
Is this transaction data?
No. This report aggregates ranges that other firms have published, most of them advisory or brokerage ranges rather than audited deal data, and it is not Tenet M&A’s own transaction data. Only three sources describe a transaction basis. Every figure should be treated as orientation rather than pricing, and an individual practice routinely falls outside every range on the page.
What is the difference between an EBITDA multiple and an SDE multiple?
SDE, or seller’s discretionary earnings, adds the owner’s own compensation back to earnings and is used for smaller, owner-operated practices. EBITDA is used for larger practices with management in place, and some sources further adjust to post-MSO EBITDA by deducting a market clinical wage for the owner. Because the earnings bases differ, the multiples are not comparable, and a 2 times SDE figure and a 5 times EBITDA figure can describe the same practice.
How can a practice move to a higher multiple?
By changing tier rather than specialty: adding associate providers so production no longer depends on the owner, building ancillary or recurring revenue, diversifying payers, and cleaning up financials so every add-back is defensible. These are the factors sources most consistently cite for the top of a band, and most take one to three years, which is why a valuation obtained early is more useful than one obtained at the point of sale.
Find out what your practice is worth
Get a confidential, healthcare-specific valuation from a Tenet advisor, with no obligation.

